Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Merck adopts Genedata Biologics

Share this on social media:

Genedata, a provider of software solutions for R&D has announced that Merck, has implemented Genedata Biologics to scale-up their bispecific antibody discovery programs and to develop innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases.

The need to systematically evaluate large panels of multi-specific antibodies poses new bottlenecks for antibody engineering with regard to throughput and automation. Multiple next-generation antibody formats must be tested, which results in significant combinatorial complexity.

Genedata Biologics increases throughput by enabling the systematic design and cloning of large numbers of novel, highly engineered molecules and enabling automation of downstream expression, purification, and characterisation processes. 

Back in 2015, Merck deployed Genedata Biologics as its central biologics workflow platform across Merck Biopharma antibody discovery units in Germany, Israel, and the US, where Merck operates its biopharmaceutical business as EMD Serono. Since its successful roll-out, the platform's applications have been continuously expanded to groups including phage and yeast display, B-cell cloning, protein engineering, microbial and mammalian expression, purification, analytics and QC.

Today, Genedata Biologics is Merck's central repository for biologics candidate data, enabling transparent decision making on the most promising candidates to promote into clinical development.

‘We are delighted to see Merck expand the application scope of Genedata Biologics to their innovative bispecific R&D programs,’ said Dr Othmar Pfannes, CEO of Genedata. ‘It is exciting to see how our platform enables the adoption of new processes in this quickly evolving field. We are committed to further expanding the platform in close collaboration with our growing customer base to support new technologies, such as cell and gene therapies, RNA therapeutics, novel scaffolds, and other innovative therapeutic platforms.’

In the six short years since its first release in 2011, Genedata Biologics has been adopted by more than many of the world's leading biopharmaceutical companies. Genedata's collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customisations, project management, training, and roll out and deployment support.

Company: